Segantii Capital Management Ltd Makes New $1.41 Million Investment in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Segantii Capital Management Ltd acquired a new position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,900 shares of the financial services provider’s stock, valued at approximately $1,407,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Global Retirement Partners LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 2.6% during the first quarter. Global Retirement Partners LLC now owns 3,880 shares of the financial services provider’s stock worth $434,000 after purchasing an additional 99 shares in the last quarter. Dearborn Partners LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 1.5% during the first quarter. Dearborn Partners LLC now owns 6,617 shares of the financial services provider’s stock worth $740,000 after purchasing an additional 100 shares in the last quarter. Northstar Asset Management LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 2.5% during the first quarter. Northstar Asset Management LLC now owns 4,060 shares of the financial services provider’s stock worth $454,000 after purchasing an additional 100 shares in the last quarter. Acropolis Investment Management LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 0.9% during the second quarter. Acropolis Investment Management LLC now owns 11,377 shares of the financial services provider’s stock worth $1,241,000 after purchasing an additional 100 shares in the last quarter. Finally, Family Firm Inc. lifted its position in shares of iShares Nasdaq Biotechnology ETF by 1.3% during the first quarter. Family Firm Inc. now owns 7,600 shares of the financial services provider’s stock worth $850,000 after purchasing an additional 101 shares in the last quarter. Institutional investors own 72.66% of the company’s stock.

Shares of NASDAQ IBB traded down $1.31 during trading on Friday, reaching $105.07. 2,026,649 shares of the stock were exchanged, compared to its average volume of 2,331,389. The business’s 50-day moving average price is $106.83. iShares Nasdaq Biotechnology ETF has a twelve month low of $89.01 and a twelve month high of $122.97.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: What are municipal bonds?

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.